APA (7th ed.) Citation

Kennedy, O. J., Glassee, N., Kicinski, M., Bührer, E., Valpione, S., Gandini, S., . . . Mandala, M. Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Elsevier.

Chicago Style (17th ed.) Citation

Kennedy, Oliver John, et al. Prognostic and Predictive Importance of Body Mass Index and Type 2 Diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 Phase III Trial of Pembrolizumab Versus Placebo in Resected High-risk Stage III Melanoma. Elsevier.

MLA (9th ed.) Citation

Kennedy, Oliver John, et al. Prognostic and Predictive Importance of Body Mass Index and Type 2 Diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 Phase III Trial of Pembrolizumab Versus Placebo in Resected High-risk Stage III Melanoma. Elsevier.